Is triplet therapy realistic for all relapsed/refractory multiple myeloma patients?

Professor Graham Jackson and Professor Philippe Moreau discuss whether triplet therapy is realistic for all relapsed/refractory multiple myeloma patients.

The views expressed in this video are those of the speakers.

UK/NP/1806/0035o - August 2018

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.